Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
123.69
-2.20 (-1.75%)
Streaming Delayed Price
Updated: 3:21 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
87
88
Next >
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
May 02, 2023
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Via
MarketBeat
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
May 02, 2023
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
May 01, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Where Merck & Co Stands With Analysts
May 01, 2023
Via
Benzinga
Merck (MRK) Q1 2023 Earnings Call Transcript
April 28, 2023
MRK earnings call for the period ending March 31, 2023.
Via
The Motley Fool
FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug
May 01, 2023
Via
Benzinga
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
April 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
April 28, 2023
Via
Benzinga
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
April 28, 2023
Microsoft, Meta, Cloudflare and Crocs were among the many big movers.
Via
Investor's Business Daily
Why Merck Stock Is Trading Higher Today
April 27, 2023
Merck & Co Inc's (NYSE: MRK) Q1 sales reached $14.49 bi
Via
Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
Via
Investor's Business Daily
Germany's Possible Export Ban On Semiconductor Chemicals To China: What It Means For The U.S
April 27, 2023
Via
Benzinga
FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
April 27, 2023
The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone...
Via
Benzinga
2 of These 3 Stocks Are Lifting the Dow, but 1 Is Holding It Back
April 27, 2023
Earnings season is approaching its peak.
Via
The Motley Fool
Here's How Much $100 Invested In Merck & Co 5 Years Ago Would Be Worth Today
April 21, 2023
Via
Benzinga
Merck Makes a Bold Move That Could Transform Its Business
April 27, 2023
It's a risky deal for Merck, but it could pay off significantly.
Via
The Motley Fool
Merck: Surpasses Q1 Earnings And Revenue Estimates
April 27, 2023
Merck came out with quarterly earnings of $1.40 per share.
Via
Talk Markets
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
April 27, 2023
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher.
Via
Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
April 27, 2023
The company reported lighter-than-expected declines due to Keytruda and Gardasil.
Via
Investor's Business Daily
Merck Announces First-Quarter 2023 Financial Results
April 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
The 7 Best Stocks From Schwab’s Dividend ETF
April 26, 2023
Investors may beat the market by cherry-picking the best dividend stocks from the Schwab income exchange-traded fund.
Via
InvestorPlace
3 Biotechs That Might Get Bought Out in 2023
April 26, 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
April 25, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
This Supercharged Dividend King Stock Might Soon Run Out of Steam
April 25, 2023
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.
Via
The Motley Fool
3 Pharma Stocks That Could See a Surge in Demand in 2023
April 24, 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead
Via
InvestorPlace
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.
Via
Benzinga
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
April 21, 2023
The major indexes saw modest declines, holding in a range.
Via
Investor's Business Daily
Why Prometheus Biosciences Stock Is Skyrocketing This Week
April 20, 2023
There's nothing like a big buyout to send a clinical-stage biotech stock soaring higher.
Via
The Motley Fool
Why Shares of Bellus Health Skyrocketed This Week
April 20, 2023
The company has received a buyout offer from GSK.
Via
The Motley Fool
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
April 20, 2023
Two key tailwinds fueled a surge in the biotech's share price this week.
Via
The Motley Fool
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
87
88
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.